Core Viewpoint - Momentum investing focuses on following a stock's recent price trends, with the aim of buying high and selling higher, capitalizing on established price movements [1][2]. Company Overview: Cardinal Health (CAH) - Cardinal Health currently holds a Momentum Style Score of A, indicating strong momentum characteristics [3]. - The company has a Zacks Rank of 2 (Buy), suggesting a favorable outlook based on historical performance metrics [4]. Performance Metrics - Over the past week, CAH shares increased by 2%, outperforming the Zacks Medical - Dental Supplies industry, which rose by 0.57% [6]. - In a longer timeframe, CAH's monthly price change is 29.59%, significantly higher than the industry's 3.41% [6]. - Over the last quarter, CAH shares have risen by 41.56%, and over the past year, they have increased by 73.81%, while the S&P 500 only moved 5.68% and 14.42% respectively [7]. Trading Volume - CAH's average 20-day trading volume is 2,914,504 shares, which serves as a bullish indicator when combined with rising stock prices [8]. Earnings Outlook - In the past two months, 7 earnings estimates for CAH have been revised upwards, with no downward revisions, leading to an increase in the consensus estimate from $9.45 to $9.86 [10]. - For the next fiscal year, 6 estimates have also moved higher, with no downward revisions during the same period [10]. Conclusion - Considering the strong performance metrics and positive earnings outlook, CAH is positioned as a 2 (Buy) stock with a Momentum Score of A, making it a potential candidate for near-term investment [12].

Core Insights - Cencora reported quarterly earnings of $3.84 per share, exceeding the Zacks Consensus Estimate of $3.79 per share, and showing an increase from $3.34 per share a year ago, resulting in an earnings surprise of +1.32% [1] - The company achieved revenues of $83.73 billion for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 0.69% and reflecting a year-over-year increase from $79.05 billion [2] - Cencora's stock has increased by approximately 53.3% since the beginning of the year, significantly outperforming the S&P 500's gain of 15.1% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $4.05, with projected revenues of $87.22 billion, and for the current fiscal year, the EPS estimate is $17.37 on revenues of $342.35 billion [7] - The estimate revisions trend for Cencora was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Medical Services industry, to which Cencora belongs, is currently ranked in the bottom 41% of over 250 Zacks industries, suggesting that the industry's outlook may impact stock performance [8] - Another company in the same industry, Ardent Health, is expected to report quarterly earnings of $0.42 per share, reflecting a year-over-year change of +121.1%, with revenues anticipated to be $1.55 billion, up 7.1% from the previous year [9][10]

Core Insights - Cardinal Health reported quarterly earnings of $2.55 per share, exceeding the Zacks Consensus Estimate of $2.21 per share, and showing an increase from $1.88 per share a year ago, resulting in an earnings surprise of +15.38% [1] - The company achieved revenues of $64.01 billion for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 8.39%, compared to $52.28 billion in the same quarter last year [2] - Cardinal shares have increased by approximately 39.1% since the beginning of the year, outperforming the S&P 500's gain of 17.2% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $2.23, with expected revenues of $62.1 billion, and for the current fiscal year, the EPS estimate is $9.45 on revenues of $249 billion [7] - The estimate revisions trend for Cardinal was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Medical - Dental Supplies industry, to which Cardinal belongs, is currently ranked in the top 21% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - McKesson, another company in the same industry, is expected to report quarterly earnings of $8.92 per share, reflecting a year-over-year change of +26.2%, with revenues anticipated to be $104.66 billion, up 11.8% from the previous year [9][10]

Group 1: Earnings Performance - Cardinal Health reported quarterly earnings of $2.08 per share, exceeding the Zacks Consensus Estimate of $2.03 per share, and up from $1.84 per share a year ago, representing an earnings surprise of +2.46% [1] - The company posted revenues of $60.16 billion for the quarter ended June 2025, slightly missing the Zacks Consensus Estimate by 0.84%, but up from $59.87 billion year-over-year [2] Group 2: Stock Performance and Outlook - Cardinal shares have increased by approximately 33.3% since the beginning of the year, significantly outperforming the S&P 500's gain of 8.4% [3] - The current consensus EPS estimate for the upcoming quarter is $2.17 on revenues of $57.99 billion, and for the current fiscal year, it is $9.21 on revenues of $248.27 billion [7] Group 3: Industry Context - The Medical - Dental Supplies industry, to which Cardinal belongs, is currently ranked in the top 37% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Pro-Dex, Inc., another company in the same industry, is expected to report quarterly earnings of $0.47 per share, reflecting a year-over-year change of +2.2% [9]

Core Viewpoint - Investors are seeking growth stocks that can deliver above-average growth and exceptional returns, but identifying such stocks can be challenging due to their inherent risks and volatility [1] Group 1: Growth Stock Identification - The Zacks Growth Style Score system simplifies the process of finding promising growth stocks by analyzing a company's real growth prospects beyond traditional metrics [2] - Cencora (COR) is highlighted as a recommended stock with a favorable Growth Score and a top Zacks Rank [2] Group 2: Earnings Growth - Earnings growth is a critical factor for growth investors, with double-digit growth being particularly attractive as it indicates strong future prospects [4] - Cencora has a historical EPS growth rate of 14.5%, with projected EPS growth of 15.3% this year, surpassing the industry average of 14.5% [5] Group 3: Cash Flow Growth - High cash flow growth is essential for growth-oriented companies, allowing them to fund new projects without relying on external financing [6] - Cencora's year-over-year cash flow growth is 12.9%, significantly higher than the industry average of -1.1% [6] - The company's annualized cash flow growth rate over the past 3-5 years is 14.1%, compared to the industry average of 8% [7] Group 4: Earnings Estimate Revisions - Positive trends in earnings estimate revisions are correlated with stock price movements, making them an important consideration for investors [8] - Cencora's current-year earnings estimates have been revised upward, with the Zacks Consensus Estimate increasing by 0.9% over the past month [8] Group 5: Overall Positioning - Cencora has achieved a Growth Score of A and a Zacks Rank of 2 due to positive earnings estimate revisions, positioning it well for potential outperformance [10]

Core Viewpoint - McKesson reported quarterly earnings of $8.26 per share, exceeding the Zacks Consensus Estimate of $8.23 per share, and showing an increase from $7.88 per share a year ago, indicating a positive earnings surprise of +0.36% [1][2] Financial Performance - The company achieved revenues of $97.83 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 1.82%, and up from $79.28 billion in the same quarter last year [2] - Over the last four quarters, McKesson has exceeded consensus EPS estimates three times and topped revenue estimates two times [2] Stock Performance - McKesson shares have increased approximately 24.5% since the beginning of the year, significantly outperforming the S&P 500's gain of 7.1% [3] Future Outlook - The company's earnings outlook is crucial for investors, with current consensus EPS estimates at $8.61 for the coming quarter and $37.26 for the current fiscal year, alongside projected revenues of $103.81 billion and $406.16 billion respectively [7] - The Zacks Rank for McKesson is currently 2 (Buy), indicating expectations for the stock to outperform the market in the near future [6] Industry Context - The Medical - Dental Supplies industry, to which McKesson belongs, is currently in the top 25% of over 250 Zacks industries, suggesting a favorable environment for stock performance [8]

Company Performance - Teladoc reported a quarterly loss of $0.19 per share, better than the Zacks Consensus Estimate of a loss of $0.27, and an improvement from a loss of $0.28 per share a year ago, representing an earnings surprise of +29.63% [1] - The company posted revenues of $631.9 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 1.77%, although this is a decrease from year-ago revenues of $642.44 million [2] - Over the last four quarters, Teladoc has surpassed consensus EPS estimates three times and topped consensus revenue estimates four times [2] Stock Outlook - Teladoc shares have underperformed the market, losing about 9.8% since the beginning of the year, while the S&P 500 has gained 8.6% [3] - The current consensus EPS estimate for the coming quarter is -$0.21 on revenues of $627.2 million, and for the current fiscal year, it is -$1.21 on revenues of $2.51 billion [7] Industry Context - The Medical Services industry, to which Teladoc belongs, is currently in the top 37% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% of industries [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that industry outlook can materially impact stock performance [5][8]